Study reveals novel approach to promote efficient uptake of ASOs into cancer cells

Antisense oligonucleotides (ASOs) are promising next-generation drugs that can block harmful messages from genes, potentially treating diseases like cancer. However, delivering ASOs into cancer cells has been a major challenge as the cells have gatekeeper molecules that prevent their entry. Researchers at Osaka University have developed a new compound called L687, which opens specific calcium permeable channels on the surface of cancer cells, allowing ASOs to enter. This discovery has significant implications for enhancing the efficacy of ASO therapy in treating various types of cancer, including lung and prostate cancer. The study was published in the journal Nucleic Acids Research.

Source link

error: Content is protected !!